Home > Rheumatology > EULAR 2025 > ACPA positivity plus musculoskeletal pain does not equal clinical arthritis over time for all

ACPA positivity plus musculoskeletal pain does not equal clinical arthritis over time for all

Presented by
Dr Simon Ahammar, Linköping University, Sweden
Conference
EULAR 2025
Not all roads lead to rheumatoid arthritis (RA), according to a decade-long study on anti-citrullinated protein antibodies (ACPA)-positive individuals with musculoskeletal pain.

Over a 10-year period, a prospective study followed Swedish patients without arthritis who tested positive for ACPA and had musculoskeletal pain, with the aim of finding out more about the disease course and prognostic factors [1]. Patients enrolled between 2010 and 2013 were followed for the development of clinical arthritis in ≥1 joint as the primary outcome, over a median period of 128 months. Additional outcomes included fulfilling ACR/EULAR classification criteria for RA.

The study cohort consisted of 82 patients with a mean age of 52 at baseline. Furthermore, 81% were women, 29% were rheumatoid factor (RF) positive, and the ACPA levels were categorised as high in 61% and low in 39% of cases.

Over the follow-up period, 63% progressed to clinical arthritis. “The median time to develop arthritis was 16 months,” Dr Simon Ahammar (Linköping University, Sweden) stated. At the 10-year clinical assessment, 40 out of the 66 (60%) patients who completed the study had developed arthritis. While all of them fulfilled the ACR/EULAR criteria for RA, 28% of them were not diagnosed with clinical RA. The diagnoses of these patients were transient arthritis without the need for a DMARD treatment (13%), osteoarthritis (8%), and psoriatic arthritis (7%).

A multivariate model identified 3 significant predictors of long-term progression to arthritis: ACPA levels (P<0.001), RF levels (P=0.020), and high RF levels (P=0.018), the latter detected after dichotomisation into high and low categories.

“Other factors, such as shared epitope or symptom duration, tender joint counts, or C-reactive protein levels, were not predictive of arthritis development,” Dr Ahammar informed. He concluded by noting that a future analysis of this cohort will include radiographic findings.

  1. Ahammar S, et al. Results of a 10-year prospective follow-up of patients with musculoskeletal pain and anti-citrullinated protein antibodies -not every arthritis is rheumatoid arthritis, despite criteria fulfilment. OP0110, EULAR 2025, 11–14 June, Barcelona, Spain.
Copyright ©2025 Medicom Medical Publishers

 

 



Posted on